Conditions: Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 32
Healthy volunteers: no

Brief summary:
This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant. The study is open to adults with type 1 or type 2 diabetes and will last about 50 days.

Detailed description:

Arms:
arm 1: One dose of 3 milligram (mg) NG administered in one of four study periods. arm 2: Two NG doses, 3 mg each dose, administered 15 minutes apart, in the same nostril, in one of four study periods. arm 3: Two NG doses, 3 mg each dose, administered 15 minutes apart, in opposite nostrils, in one of four study periods. arm 4: Two NG doses, 3 mg each dose, administered one immediately after the other, in opposite nostrils, in one of four study periods.

Interventions: intervention 1: Nasal Glucagon
Intervention descriptions: intervention 1: Administered intranasally.

Protocol document: